Hints and tips:
Related Special Reports
...Merck is offering $11bn for Prometheus Biosciences which is researching a monoclonal antibody treatment for inflammatory bowel disease. GSK is paying double the undisturbed price for Bellus....
...Merck recently agreed to buy Prometheus Biosciences for $10.8bn, while last month Pfizer announced the industry’s largest deal for four years, acquiring oncology biotech Seagen for a total enterprise value...
...Several senior vaccine executives have left GSK this year to join smaller companies, including Amin Khan, who went to GreenLight Biosciences, Emmanuel Hanon, who joined Viome, and Amir Reichman, who now...
...During phase 3 trials, the safety and effectiveness of the SK Bioscience GBP510 vaccine will be measured against the Oxford/AstraZeneca jab....
...AstraZeneca has admitted that the launch of Covid-19 vaccine production at Siam Bioscience, the Thai pharmaceutical company owned by the billionaire King Maha Vajiralongkorn, had been “complicated”, but...
...Siam Bioscience will produce 200m doses of the coronavirus jab, including for export....
...Its contract for Thailand’s Siam Bioscience to produce up to 200m vaccine doses a year as its south-east Asian production hub was one of two dozen worldwide....
...Briefly GlaxoSmithKline and SK Bioscience of South Korea said they have begun a late-stage clinical trial of SK’s Covid vaccine candidate in combination with GSK’s experimental booster shot....
...Mr Thanathorn said that while Siam Bioscience was a newcomer to the vaccine industry, “it’s now becoming the biggest player” in Thailand. Siam Bioscience declined a request for comment....
...That is the real issue,” said Shahid Jameel, director of Ashoka University’s Trivedi School of Biosciences. “This is a political decision, whatever they may say.”...
...The supply of lipid nanoparticles is “fairly restricted” in Europe, said Andrey Zarur, chief executive of GreenLight BioSciences, a Massachusetts-based company that works with messenger RNA, including in...
...But Andrey Zarur, chief executive of GreenLight Biosciences, which is developing an mRNA Covid-19 vaccine, said the FDA had informed the company that it would not need to redo safety trials if all of the...
...Eric Topol, director of the Scripps Research Translational Institute, part of a Californian hub for biosciences, said AstraZeneca’s data stood out for the wrong reasons....
...Shahid Jameel, director of the Trivedi School of Biosciences in India, says that, given the pandemic’s ferocity in some rich countries, the staggered start to the vaccine rollout is inevitable....
...Its portfolio — which spans technology, artificial intelligence and bioscience — includes companies such as Oxford Nanoimaging, Vaccitech and Oxford Flow....
...Horizon Discovery half-year results One UK company that may see only upside from an international move is small gene editing bioscience group Horizon Discovery....
...Arix Bioscience Rather than developing technology to make pharma R&D quicker and more effective, Arix’s approach to boosting productivity involves “operating like a venture capital group”, said Joe Anderson...
...Earlier this year Zhi Hong, an 11-year veteran of GlaxoSmithKline who led the company’s infectious diseases business, launched Brii Biosciences, which raised $260m from investors, including venture capital...
Pfizer among those risking backlash with new year increases on many medicines
...Group; Kate Swann/SSP Group; Bruce Thompson/Diploma Winner: Geoff Drabble/Ashtead Group Award sponsor: Citi Commercial Bank New Company of the Year Award Shortlist: Alfa Financial Software Holdings; Arix Bioscience...
...The Crick receives £117m a year in core funding from the MRC, CRUK and Wellcome, and its work covers a broad sweep of bioscience, with potential applications for conditions from cancer and heart disease...
...Perhaps Rex Bionics was brought to the market too soon by Jeremy Curnock Cook, the bioscience investment veteran who is deputy chairman....
...“We are seeing the development of a capital base in the UK that is drawing in a lot of management talent,” says Joe Anderson, chief executive of Arix Bioscience, a specialist investor that listed on the...
...The second, by Pacific Biosciences last month, was “without merit”, said Dr Sanghera....
International Edition